{
  "items": "33",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Celularity Inc. Comments on CMS Withdrawal of Skin Substitute Coverage Determinations",
      "url": "https://www.quiverquant.com/news/Celularity+Inc.+Comments+on+CMS+Withdrawal+of+Skin+Substitute+Coverage+Determinations",
      "time_published": "20251226T140910",
      "authors": [
        "Robert J. Hariri",
        "Carlos Ramirez"
      ],
      "summary": "Celularity Inc. has responded to the CMS withdrawal of Local Coverage Determinations (LCDs) for skin substitute products, effective January 1, 2026. While 158 other products will lose Medicare coverage, Celularity's Biovance\u00ae products remain eligible, positioning the company favorably. CEO Dr. Robert J. Hariri highlighted Biovance\u00ae's effectiveness through real-world evidence and the company's advanced manufacturing capabilities.",
      "banner_image": "https://www.quiverquant.com/images/celu_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.916594"
        },
        {
          "topic": "finance",
          "relevance_score": "0.707873"
        }
      ],
      "overall_sentiment_score": 0.414663,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.412832",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Celularity Secures New Financing To Support Strategic Shift",
      "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/36783992/celularity-secures-new-financing-to-support-strategic-shift/",
      "time_published": "20251224T220855",
      "authors": [
        "NULL"
      ],
      "summary": "Celularity Inc. has secured new financing totaling up to $12 million from investor Philip A. Barach, comprising a senior secured term loan and a convertible note facility, along with warrants. This funding aims to support ongoing operations and a strategic shift towards leveraging its placenta-derived platform in longevity and healthy aging. The company's stock, CELU, is rated as \"Underperform\" by TipRanks\u2019 AI Analyst, Spark, due to financial instability and bearish technical indicators.",
      "banner_image": "NULL",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.937120"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.819222"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.720639"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.600264"
        }
      ],
      "overall_sentiment_score": -0.128287,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.230938",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.628009",
          "ticker_sentiment_score": "-0.179086",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "F",
          "relevance_score": "0.620692",
          "ticker_sentiment_score": "0.152909",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "INTC",
          "relevance_score": "0.600645",
          "ticker_sentiment_score": "-0.223153",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.615451",
          "ticker_sentiment_score": "-0.123861",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Celularity Closes Financing Transactions",
      "url": "https://www.citybiz.co/article/787519/celularity-closes-financing-transactions/",
      "time_published": "20251224T010947",
      "authors": [
        "NULL"
      ],
      "summary": "Celularity Inc. (Nasdaq: CELU) has announced the closing of financing transactions with Philip A. Barach, securing $10.00 million in gross proceeds with potential for an additional $2.0 million. This financing, comprising a senior secured term loan and secured convertible notes, aims to bolster Celularity's financial position and support its focus on leveraging its placental-derived platform for healthy aging and performance optimization. The company plans to articulate its refined corporate strategy in the new year, aligning scientific capabilities with long-term opportunities in longevity and age-related diseases.",
      "banner_image": "https://www.citybiz.co/wp-content/uploads/2025/12/celuarity.jpg",
      "source": "citybiz",
      "category_within_source": "General",
      "source_domain": "citybiz",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.904996"
        }
      ],
      "overall_sentiment_score": 0.422399,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.400622",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Celularity Secures New Financing To Support Strategic Shift",
      "url": "https://www.tipranks.com/news/company-announcements/celularity-secures-new-financing-to-support-strategic-shift",
      "time_published": "20251223T230910",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Celularity (CELU) recently secured $10 million in financing, with an additional $2 million possible, through secured and convertible notes from investor Philip Barach. This funding package, which includes warrants and board observer rights, enhances Celularity's immediate liquidity and supports a strategic pivot towards longevity and healthy aging applications. The company aims to leverage its placenta-derived platform to address age-related and degenerative diseases, reshaping its portfolio for long-term shareholder value.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1279492897-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.923839"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.846614"
        }
      ],
      "overall_sentiment_score": -0.201529,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.248088",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Celularity Announces Closing of Financing Transactions",
      "url": "https://www.manilatimes.net/2025/12/23/tmt-newswire/globenewswire/celularity-announces-closing-of-financing-transactions/2248354",
      "time_published": "20251223T211011",
      "authors": [
        "GlobeNewswire"
      ],
      "summary": "Celularity Inc. announced the closing of financing transactions with Philip A. Barach, securing $10.00 million in gross proceeds with a potential for an additional $2.0 million. This financing, consisting of a senior secured term loan and convertible notes, aims to strengthen Celularity's financial position and support its focus on leveraging its placental-derived platform for healthy aging and performance optimization. The company plans to articulate its corporate strategy more fully in the new year to align scientific capabilities with long-term opportunities in longevity and age-related diseases.",
      "banner_image": "https://cdn4.premiumread.com/?url=https://www.manilatimes.net/theme_manilatimes/images/TMT_1920x1008.jpg&w=1920&q=100&f=webp&v=1",
      "source": "The Manila Times",
      "category_within_source": "General",
      "source_domain": "The Manila Times",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.944532"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.827448"
        }
      ],
      "overall_sentiment_score": 0.482067,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.484353",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Longevity-focused biotech Celularity raises $10M for aging research",
      "url": "https://www.stocktitan.net/news/CELU/celularity-announces-closing-of-financing-lzod23nzinl9.html",
      "time_published": "20251223T011011",
      "authors": [
        "NULL"
      ],
      "summary": "Celularity Inc. announced the closing of financing transactions that generated $10 million in gross proceeds, with potential for an additional $2 million. This funding package includes a $7 million senior secured term loan and up to $5 million in secured convertible notes, alongside warrants for 3,707,657 shares. The biotech company, focused on regenerative medicine and age-related diseases, plans to use the proceeds to support ongoing operations, strategic initiatives, and its longevity-focused platform derived from placental cells.",
      "banner_image": "https://ml.globenewswire.com/media/MGYxNWI4YWUtMjliYi00OGEwLWEwOGMtMjFiZDJjYWUwOGVmLTEyMTY1NjItMjAyNS0xMi0yMi1lbg==/tiny/Celularity-Inc-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.940099"
        },
        {
          "topic": "finance",
          "relevance_score": "0.818946"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.916774"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.730452"
        }
      ],
      "overall_sentiment_score": 0.234,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.234320",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Celularity Announces Closing of Financing Transactions",
      "url": "https://investingnews.com/celularity-announces-closing-of-financing-transactions/",
      "time_published": "20251222T230826",
      "authors": [],
      "summary": "Celularity Inc. (Nasdaq: CELU) has announced the closing of financing transactions with Philip A. Barach, securing $10.00 million in gross proceeds with potential for an additional $2.0 million. This financing, comprising a senior secured term loan and convertible notes, is aimed at bolstering Celularity's operations and strategic focus on placental-derived platforms for age-related and degenerative diseases. The company plans to articulate its refined corporate strategy, emphasizing longevity and age-related disease, in the new year.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=33034115&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.915953"
        }
      ],
      "overall_sentiment_score": 0.422635,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.430073",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Celularity secures $10 million financing from DoubleLine co-founder",
      "url": "https://www.investing.com/news/company-news/celularity-secures-10-million-financing-from-doubleline-cofounder-93CH-4420046",
      "time_published": "20251222T040500",
      "authors": [
        "Investing.com"
      ],
      "summary": "Celularity Inc. has secured $10 million in financing from Philip A. Barach, co-founder of DoubleLine Capital LP, amidst financial challenges including a significant debt burden and a declining stock price. The financing package includes a senior secured term loan and convertible notes, along with warrants for Class A Common Stock. The company, focused on placental-derived biomaterials and cell therapies, aims to strengthen its financial position and advance its pipeline, despite recent net losses.",
      "banner_image": "https://i-invdn-com.investing.com/news/world_news_2_69x52._800x533_L_1419494365.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.812872"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.940906"
        }
      ],
      "overall_sentiment_score": 0.108386,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.106365",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Celularity Shareholders Reject Expansion of Equity Incentive Plan",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/CELU-Q/pressreleases/36731486/celularity-shareholders-reject-expansion-of-equity-incentive-plan/",
      "time_published": "20251221T010947",
      "authors": [
        "NULL"
      ],
      "summary": "Celularity Inc. shareholders rejected a proposal to expand the company's 2021 Equity Incentive Plan by 3.5 million shares at their Annual Meeting on December 19, 2025. This move signals shareholder opposition to further equity-based dilution and could restrict future stock compensation. Despite the rejection, shareholders reelected three Class I directors and ratified EisnerAmper LLP as the independent auditor.",
      "banner_image": "NULL",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.949399"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.735662"
        },
        {
          "topic": "finance",
          "relevance_score": "0.640313"
        }
      ],
      "overall_sentiment_score": 0.012943,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "0.314555",
          "ticker_sentiment_score": "0.020712",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Celularity secures up to $12 million in financing for longevity focus",
      "url": "https://ng.investing.com/news/company-news/celularity-secures-up-to-12-million-in-financing-for-longevity-focus-93CH-2261429",
      "time_published": "20251219T000909",
      "authors": [
        "NULL"
      ],
      "summary": "Celularity Inc. has secured up to $12 million in financing through a senior secured term loan and convertible notes from Philip A. Barach to bolster its regenerative medicine mission, focusing on placental-derived technologies for longevity. This capital infusion is crucial for the company, which has been facing financial challenges and has a significant debt burden. The financing aims to provide flexibility for the company to refine its focus and position for a more disciplined future.",
      "banner_image": "https://i-invdn-com.investing.com/news/world_news_2_69x52._800x533_L_1419494365.jpg",
      "source": "Investing.com Nigeria",
      "category_within_source": "General",
      "source_domain": "Investing.com Nigeria",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.904216"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.819632"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.732078"
        }
      ],
      "overall_sentiment_score": 0.33411,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.342282",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Celularity secures up to $12 million in financing for longevity focus",
      "url": "https://www.investing.com/news/company-news/celularity-secures-up-to-12-million-in-financing-for-longevity-focus-93CH-4415878",
      "time_published": "20251219T000846",
      "authors": [
        "Investing.com"
      ],
      "summary": "Celularity Inc. has secured up to $12 million in financing through a senior secured term loan and convertible notes from Philip A. Barach, co-founder of DoubleLine Capital LP. This capital infusion is crucial for the regenerative medicine company, which faces financial challenges including significant debt and a low current ratio. The funding is intended to advance Celularity's core placental-derived technologies and support its focus on longevity.",
      "banner_image": "https://i-invdn-com.investing.com/news/world_news_2_69x52._800x533_L_1419494365.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.814808"
        },
        {
          "topic": "finance",
          "relevance_score": "0.741538"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.932694"
        }
      ],
      "overall_sentiment_score": 0.458902,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.477328",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Celularity secures up to $12 million in financing for longevity focus",
      "url": "https://au.investing.com/news/company-news/celularity-secures-up-to-12-million-in-financing-for-longevity-focus-93CH-4178195",
      "time_published": "20251218T201028",
      "authors": [
        "Investing.com"
      ],
      "summary": "Celularity Inc. has secured binding financing agreements for up to $12 million from Philip A. Barach, co-founder of DoubleLine Capital LP, amidst financial challenges and a significant debt burden. This capital, including a senior secured term loan and convertible notes, is aimed at advancing the company's core placental-derived technologies focused on longevity. The financing is expected to provide flexibility for Celularity to refine its mission and focus on its therapeutic solutions.",
      "banner_image": "https://i-invdn-com.investing.com/news/world_news_2_69x52._800x533_L_1419494365.jpg",
      "source": "Investing.com Australia",
      "category_within_source": "General",
      "source_domain": "Investing.com Australia",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.810414"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.905058"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.707010"
        }
      ],
      "overall_sentiment_score": 0.274521,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.275427",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Celularity Inc. Secures Up to $12 Million in Financing to Advance Strategic Priorities in Longevity and Human Performance",
      "url": "https://www.quiverquant.com/news/Celularity+Inc.+Secures+Up+to+%2412+Million+in+Financing+to+Advance+Strategic+Priorities+in+Longevity+and+Human+Performance",
      "time_published": "20251218T191028",
      "authors": [
        "NULL"
      ],
      "summary": "Celularity Inc. has announced securing up to $12 million in financing through a senior secured term loan and convertible note financing with investor Philip A. Barach. This funding aims to advance the company's strategic priorities in longevity and human performance, focusing on its placental-derived technologies. The financing, conditional on formal agreements, is expected to provide initial proceeds of $10 million, with potential for an additional $2 million.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.904449"
        },
        {
          "topic": "finance",
          "relevance_score": "0.849720"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.726258"
        }
      ],
      "overall_sentiment_score": 0.416453,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.394714",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "DoubleLine co-founder backs up to $12M funding plan for longevity",
      "url": "https://www.stocktitan.net/news/CELU/celularity-reaches-binding-term-sheets-on-financing-transactions-to-d6ytskgi4eao.html",
      "time_published": "20251218T191028",
      "authors": [
        "NULL"
      ],
      "summary": "Celularity (CELU) has secured binding term sheets for up to $12 million in private capital to advance its longevity and human performance initiatives. This financing, backed by Philip A. Barach, co-founder of DoubleLine Capital LP, includes a $7.0 million senior secured term loan and up to $5.0 million in secured convertible notes. The company aims to strengthen its financial position and further develop its placental-derived technologies.",
      "banner_image": "https://ml.globenewswire.com/media/NDQxZDVhZDYtZTljMC00NzQ4LTg5NTYtZDMxMTgwNTM5NGIxLTEyMTY1NjItMjAyNS0xMi0xOC1lbg==/tiny/Celularity-Inc-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.935104"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.800529"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.749874"
        }
      ],
      "overall_sentiment_score": 0.266519,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.293656",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision",
      "url": "https://investingnews.com/celularity-reaches-binding-term-sheets-on-financing-transactions-to-support-its-strategic-vision/",
      "time_published": "20251218T000910",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Celularity Inc. announced it has entered into binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, potentially providing up to $12 million in capital. This financing aims to support Celularity's strategic priorities around longevity and the preservation of human performance, focusing on advancing its core placental-derived technologies. The transactions reflect a long-term commitment to evolving Celularity's mission and aligning its capital structure for a more disciplined future.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=33034115&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.834518"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.937738"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.711874"
        }
      ],
      "overall_sentiment_score": 0.407107,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.423399",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding",
      "url": "https://www.sahmcapital.com/news/content/there-is-a-reason-celularity-incs-nasdaqcelu-price-is-undemanding-2025-12-15",
      "time_published": "20251216T011028",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Celularity Inc. (NASDAQ:CELU) has a low price-to-sales (P/S) ratio of 1.1x, significantly lower than the biotech industry average, indicating bearish sentiment. This is attributed to a recent 16% decrease in revenue, despite a strong 117% rise over the last three years. The market anticipates continued limited growth, reflected in its undemanding P/S ratio compared to the industry's expected 52% growth.",
      "banner_image": "https://images.simplywall.st/asset/chart/408304689-ps-multiple-vs-industry-1-dark-2/1765818274978",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.934705"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.839043"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.705471"
        }
      ],
      "overall_sentiment_score": -0.214466,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.203162",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Celularity, Inc. Forms Death Cross, Signaling Potential Bearish Trend Ahead",
      "url": "https://www.marketsmojo.com/news/stocks-in-action/celularity-inc-forms-death-cross-signaling-potential-bearish-trend-ahead-3726003",
      "time_published": "20251124T151700",
      "authors": [
        "NULL"
      ],
      "summary": "Celularity, Inc. has encountered a Death Cross, a technical indicator suggesting a potential bearish trend, despite a recent 1-day performance increase. The company's technical indicators, including daily moving averages, MACD, and Bollinger Bands, confirm a bearish outlook. Longer-term performance remains troubling, with significant declines over the past year and five years compared to the S&P 500.",
      "banner_image": "NULL",
      "source": "Markets Mojo",
      "category_within_source": "General",
      "source_domain": "Markets Mojo",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.945497"
        }
      ],
      "overall_sentiment_score": -0.63071,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.627289",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "CELU SEC Filings - Celularity Inc 10-K, 10-Q, 8-K Forms",
      "url": "https://www.stocktitan.net/sec-filings/CELU/",
      "time_published": "20251108T034341",
      "authors": [],
      "summary": "This article provides a comprehensive overview of Celularity Inc.'s (CELU) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights how Stock Titan's platform simplifies these complex documents with AI-powered summaries and real-time alerts. The article also details recent filings, such as director equity awards, Q3 2025 financial results showing liquidity strain, and a proxy statement for the upcoming annual meeting.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.906462"
        },
        {
          "topic": "finance",
          "relevance_score": "0.849430"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.721418"
        }
      ],
      "overall_sentiment_score": -0.413315,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.414002",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Celularity and DefEYE, Inc. Form Partnership to Advance Growth of Regenerative Therapies in Eyecare",
      "url": "https://www.visionmonday.com/eyecare/article/celularity-and-defeye-inc-form-partnership-to-advance-growth-of-regenerative-therapies-in-eyecare/",
      "time_published": "20251031T121500",
      "authors": [
        "Staff"
      ],
      "summary": "Celularity Inc. has formed a strategic partnership with DefEYE, Inc., a new ophthalmic product and technology company, to advance regenerative therapies in eyecare. This collaboration includes an exclusive license and pricing agreement, established after Celularity's in-kind investment in DefEYE's $12 million seed funding round. DefEYE will utilize the proceeds to launch a portfolio of decellularized biologic solutions for eyecare, with Celularity serving as the exclusive contract manufacturer.",
      "banner_image": null,
      "source": "VisionMonday.com",
      "category_within_source": "General",
      "source_domain": "VisionMonday.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.934326"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.811523"
        },
        {
          "topic": "finance",
          "relevance_score": "0.647308"
        }
      ],
      "overall_sentiment_score": 0.404038,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.436879",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Investing News Network",
      "url": "https://investingnews.com/celularity-announces-peer-reviewed-publication-of-phase-2-clinical-trial-results-demonstrating-the-safety-and-efficacy-of-human-placenta-derived-cells-for-diabetic-foot-ulcers-complicated-by-periphera/",
      "time_published": "20251015T042233",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Celularity announced the publication of its Phase 2 clinical trial results demonstrating the safety and efficacy of PDA-002, a human placenta-derived cell therapy, for diabetic foot ulcers complicated by peripheral artery disease. The study, published in the International Wound Journal, showed that PDA-002 achieved durable wound healing and a favorable safety profile with just two intramuscular doses. This therapy may soon be available in Florida for wound care under a new state law, highlighting its potential to address a significant unmet medical need.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=33034115&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.919988"
        }
      ],
      "overall_sentiment_score": 0.028773,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "0.312547",
          "ticker_sentiment_score": "0.042858",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Celularity terminates CFO, appoints interim replacement",
      "url": "https://www.investing.com/news/company-news/-celularity-terminates-cfo-appoints-interim-replacement-93CH-4089691",
      "time_published": "20251006T162000",
      "authors": [
        "Investing.com"
      ],
      "summary": "Celularity Inc. (NASDAQ:CELU) announced the termination of CFO David Beers and the appointment of Joseph DosSantos as interim CFO. The company, which faces significant financial challenges including a high debt-to-equity ratio, stated Beers' termination was \"without cause\" and not related to financial performance. Celularity has also hired CFO Squad for financial and SEC reporting support during this transition period.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.904758"
        },
        {
          "topic": "finance",
          "relevance_score": "0.827369"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.701547"
        }
      ],
      "overall_sentiment_score": -0.303071,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.313775",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "CELU - Celularity Inc Latest Stock News & Market Updates",
      "url": "https://www.stocktitan.net/news/CELU/",
      "time_published": "20250818T080000",
      "authors": [
        "NULL"
      ],
      "summary": "This page provides the latest news and updates for Celularity Inc. (CELU), a clinical-stage biotechnology company focusing on placental-derived cell therapies. Recent significant events include the company's comments on CMS's withdrawal of skin substitute LCDs, closing of financing transactions, and a strategic partnership with DefEYE, Inc. for regenerative eye care therapies. Celularity also announced a major balance sheet restructuring, retiring $41.6 million in senior secured debt, and has partnered with Fountain Life to deliver stem cell therapies in Florida under a new state law.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.938163"
        }
      ],
      "overall_sentiment_score": 0.307646,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.312402",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Celularity inks manufacturing deal with BlueSphere Bio By Investing.com",
      "url": "https://au.investing.com/news/company-news/celularity-inks-manufacturing-deal-with-bluesphere-bio-93CH-3692013",
      "time_published": "20250225T000600",
      "authors": [
        "Investing.com"
      ],
      "summary": "Celularity Inc. has announced a collaboration with BlueSphere Bio, Inc. for the manufacturing of cell therapy products, utilizing Celularity's cGMP manufacturing infrastructure. This agreement focuses on BlueSphere\u2019s T cell receptor T cell therapies for high-risk leukemias, beginning with Acute Myelogenous Leukemia. The partnership highlights Celularity's strategy to leverage its robust manufacturing capabilities for both its own programs and external clients, while BlueSphere benefits from reliable production for its advancing clinical programs.",
      "banner_image": null,
      "source": "Investing.com Australia",
      "category_within_source": "General",
      "source_domain": "Investing.com Australia",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.903685"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.835353"
        },
        {
          "topic": "finance",
          "relevance_score": "0.715135"
        }
      ],
      "overall_sentiment_score": 0.34548,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.313452",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Celularity inks manufacturing deal with BlueSphere Bio",
      "url": "https://www.investing.com/news/company-news/celularity-inks-manufacturing-deal-with-bluesphere-bio-93CH-3886108",
      "time_published": "20250224T034341",
      "authors": [
        "Investing.com"
      ],
      "summary": "Celularity Inc. has announced a manufacturing collaboration with BlueSphere Bio, Inc., leveraging Celularity's cGMP facilities to produce T cell receptor (TCR) T cell therapies. The partnership, focusing on BlueSphere's therapies for high-risk leukemias, aims to utilize Celularity's manufacturing expertise while generating revenue for the company. This agreement highlights Celularity's strategy to attract clients in the cell therapy sector and advance BlueSphere's clinical programs.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.823428"
        },
        {
          "topic": "finance",
          "relevance_score": "0.710139"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.613721"
        }
      ],
      "overall_sentiment_score": 0.340973,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.319651",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Celularity amends warrant terms, secures $2.46 million funding",
      "url": "https://www.investing.com/news/sec-filings/celularity-amends-warrant-terms-secures-246-million-funding-93CH-3832113",
      "time_published": "20250127T091200",
      "authors": [
        "Investing.com"
      ],
      "summary": "Celularity has amended its warrant terms and secured $2.46 million in funding. The company, led by Chairman and CEO Robert J. Hariri, M.D., Ph.D., made this strategic move to strengthen its financial position and support ongoing projects, despite facing recent challenges like the termination of a material agreement with an institutional investor and potential Nasdaq delisting. The funding involves the 2020 Warrant for Class A common stock and the unregistered 2024 Warrant shares.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.928706"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.837895"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.729324"
        }
      ],
      "overall_sentiment_score": 0.130378,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.110794",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Celularity cancels material agreement with investor By Investing.com",
      "url": "https://au.investing.com/news/sec-filings/celularity-cancels-material-agreement-with-investor-93CH-3641405",
      "time_published": "20250126T034341",
      "authors": [],
      "summary": "Celularity Inc., a biotechnology company, has canceled a significant agreement with an institutional investor due to the investor's failure to provide the subscription amount. This termination impacts a private placement sale of over 1.2 million shares and warrants, leaving Celularity to seek alternative funding. The company, valued at $54.41 million with a concerning current ratio of 0.19 and significant debt, faces financial challenges as it navigates this development.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg",
      "source": "Investing.com Australia",
      "category_within_source": "General",
      "source_domain": "Investing.com Australia",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.916752"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.829501"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.736416"
        }
      ],
      "overall_sentiment_score": -0.38244,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.385836",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Celularity Inc. Regains Nasdaq Compliance Following Successful Filing of Quarterly Report",
      "url": "https://www.quiverquant.com/news/Celularity+Inc.+Regains+Nasdaq+Compliance+Following+Successful+Filing+of+Quarterly+Report",
      "time_published": "20241210T034341",
      "authors": [
        "NULL"
      ],
      "summary": "Celularity Inc. has announced it regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Quarterly Report on Form 10-Q for the period ending September 30, 2024. This ensures its stock remains listed on the Nasdaq Capital Market. The company addressed previous filing delays by enhancing its financial reporting infrastructure, engaging an independent audit firm, and improving internal controls, which CEO Robert J. Hariri described as a critical turning point for future growth and regulatory compliance.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.823293"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.710322"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.731236"
        }
      ],
      "overall_sentiment_score": 0.289678,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.269921",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Celularity Inc faces Nasdaq delisting over late filing By Investing.com",
      "url": "https://ca.investing.com/news/sec-filings/celularity-inc-faces-nasdaq-delisting-over-late-filing-93CH-3728267",
      "time_published": "20241129T020853",
      "authors": [
        "Investing.com"
      ],
      "summary": "Celularity Inc. has been notified by Nasdaq of potential delisting due to its failure to file a Quarterly Report on Form 10-Q by the extended deadline. The biotechnology company, specializing in pharmaceutical preparations, must submit a compliance plan by January 20, 2025, to address its significant financial challenges, including a concerning current ratio. Despite the delisting threat, Celularity's securities continue to trade, and the company expresses intent to regain compliance while actively working on product development and recent acquisitions.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
      "source": "Investing.com Canada",
      "category_within_source": "General",
      "source_domain": "Investing.com Canada",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.919963"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.825145"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.730063"
        }
      ],
      "overall_sentiment_score": -0.620846,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.614133",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Celularity Partners with Genting Berhad to Launch Stem Cell Therapies in Asia Pacific with New Facility in Bali",
      "url": "https://www.quiverquant.com/news/Celularity+Partners+with+Genting+Berhad+to+Launch+Stem+Cell+Therapies+in+Asia+Pacific+with+New+Facility+in+Bali",
      "time_published": "20241120T014300",
      "authors": [
        "NULL"
      ],
      "summary": "Celularity Inc. has partnered with Genting Berhad to introduce placenta-derived allogeneic stem cell therapeutics in the Asia Pacific region, with a new wellness and health center, Fontaine Vitale, under construction in Bali, Indonesia. This facility will use Celularity's U.S.-manufactured products to offer advanced stem cell therapies, aiming to start operations by late 2026. The collaboration seeks to address growing demand in the Asia Pacific stem cell market, projected to reach $7.2 billion by 2030, and establish Bali as a hub for medical tourism.",
      "banner_image": "https://www.quiverquant.com/images/celu_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.730581"
        }
      ],
      "overall_sentiment_score": 0.286706,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.287443",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Celularity Inc. to Host Investor and Analyst Research & Development Day",
      "url": "https://investingnews.com/celularity-inc-to-host-investor-and-analyst-research-development-day/",
      "time_published": "20240422T040916",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Celularity Inc. announced it will host an on-site and virtual Investor and Analyst Research & Development (R&D) Day on May 21, 2024. The event will highlight advancements in its placental technology platform and clinical pipeline, as well as future growth expectations for its commercial biomaterials business. Key executives, including CEO Robert J. Hariri, will present, along with an invited panel of medical experts.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=33034115&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904707"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.614429"
        }
      ],
      "overall_sentiment_score": 0.473037,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.491353",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Dr. Robert Hariri on Cell Therapeutics, Combination Therapies, and COVID-19",
      "url": "https://bioinformant.com/robert-hariri-cell-therapeutics-covid-19/",
      "time_published": "20230414T000000",
      "authors": [
        "Cade Hildreth"
      ],
      "summary": "In this interview, Dr. Robert Hariri, CEO of Celularity, Inc., discusses the company's cell therapeutics pipeline against COVID-19, focusing on the use of natural killer (NK) cells derived from the placenta. He elaborates on the scientific rationale, clinical trial design, partnerships, and manufacturing capabilities for their NK cell product (CYNK-001) and an MSC-based product (PDA-001). Dr. Hariri emphasizes the potential of cellular immunotherapeutics to reshape the future of infectious disease treatment and their synergistic role with other therapies.",
      "banner_image": null,
      "source": "BioInformant",
      "category_within_source": "General",
      "source_domain": "BioInformant",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.930517"
        },
        {
          "topic": "finance",
          "relevance_score": "0.619692"
        }
      ],
      "overall_sentiment_score": 0.037494,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "0.317995",
          "ticker_sentiment_score": "0.007803",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Celularity Inc. Announces $6 Million Registered Direct Offering",
      "url": "https://www.stocktitan.net/news/CELU/celularity-inc-announces-6-million-registered-direct-9yqicghns31w.html",
      "time_published": "20230405T090000",
      "authors": [],
      "summary": "Celularity Inc. announced a registered direct offering of approximately 9.23 million shares of its Class A common stock and warrants for an equivalent number of shares at a combined price of $0.65 per share, aiming to raise around $6 million in gross proceeds. The warrants will have an exercise price of $0.75 and existing warrants will be amended to lower their exercise price to this same value. The offering is expected to close around April 10, 2023, subject to customary conditions, with A.G.P./Alliance Global Partners acting as the sole placement agent.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.935662"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.839149"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.707058"
        }
      ],
      "overall_sentiment_score": -0.200346,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.199098",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer",
      "url": "https://www.citybiz.co/article/328578/celularity-appoints-adrian-kilcoyne-m-d-m-p-h-m-b-a-as-chief-medical-officer/",
      "time_published": "20221003T041003",
      "authors": [
        "NULL"
      ],
      "summary": "Celularity Inc. (Nasdaq: CELU), a clinical-stage biotechnology company, announced the appointment of Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Executive Vice President, Chief Medical Officer, and Head of Global Medical Affairs, Patient Safety and Patient Affairs. Dr. Kilcoyne brings over 15 years of oncology-focused clinical experience, with a strong background in advancing clinical programs through commercialization. He will be instrumental in progressing Celularity's clinical pipeline, which includes three Phase 1 studies and one IND-pending program utilizing placental-derived cellular therapeutic candidates for various cancers.",
      "banner_image": "https://www.citybiz.co/wp-content/uploads/2022/10/Adrian-Kilcoyne.jpg",
      "source": "citybiz",
      "category_within_source": "General",
      "source_domain": "citybiz",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.927431"
        },
        {
          "topic": "finance",
          "relevance_score": "0.621893"
        }
      ],
      "overall_sentiment_score": 0.428693,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CELU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.431392",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}